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A new family with a homozygous nonsense variant
in NTHL1 further delineated the clinical phenotype
of NTHL1-associated polyposis
Mays Altaraihi1, Anne-Marie Gerdes1 and Karin Wadt 1
Abstract
A new family with NTHL1-associated polyposis (NAP) is described, involving a 58-year-old male affected with >100
colorectal polyps and a 55-year-old female sibling with nine colorectal polyps. The female was also diagnosed with a
thyroid adenoma at age 40. Significantly, no malignant neoplasms have been detected in this family, which is
important to further delineate the clinical phenotype related to NAP. A review of previously reported obligate
heterozygous carriers of NTHL1 variants showed two patients affected with neoplasms at <55 years of age, generating
a study to outline the phenotypic spectrum in patients with heterozygous pathogenic NTHL1 variants relevant.
Colorectal adenomatous polyposis syndromes can be
divided into familial adenomatous polyposis (FAP),
MUTYH-associated polyposis (MAP), polymerase
proofreading-associated polyposis (PPAP) and NTHL1-
associated polyposis (NAP).
FAP is responsible for approximately 1% of all CRCs1
and is due to pathogenic variants in the adenomatous
polyposis coli (APC) gene. The APC gene is the most
frequently mutated gene associated with colorectal ade-
nomatous polyposis. TheMUTYH gene, which is involved
in the base excision repair (BER) pathway, is the second
most commonly mutated gene associated with adeno-
matous polyposis. In contrast to FAP and PPAP, MAP
shows recessive inheritance.
Recently, Weren et al. uncovered another gene in the
BER pathway, NTHL1, associated with adenomatous
polyposis and recessive inheritance2. Apart from adeno-
matous polyposis, the occurrence of ovarian cancer,
duodenal cancer, basal cell carcinoma, breast cancer,
endometrial malignancy, meningioma, and bladder cancer
have been reported in individuals with loss-of-function
variants in NTHL13.
We report a new family with NAP:
Patient 1
A 47-year-old man (patient 1) developed hematochezia
triggered by a gastrointestinal infection (Fig. 1). A colo-
noscopy was performed, identifying 23 polyps; three in the
caecum, the rest in the left colon. Polypectomy was per-
formed, and a pathology review of eight polyps showed six
tubular adenomas with either low or moderate dysplasia
and two tubulovillous adenomas, one of which had severe
dysplasia. The largest adenoma measured 20mm ×
8mm× 15mm.
The patient had no family history of colonic adenomas
or cancer, and genetic testing was not performed. How-
ever, the patient was enrolled for routine screening, and
during a 10-year span (2007–2017), annual colonoscopic
polypectomies identified and removed approximately 40
polyps. Approximately eighty percent of the polyps were
adenomas.
In June 2018, at age 58, a colonoscopy was performed,
identifying and removing 55 new polyps that had devel-
oped during the preceding 6 months. Four of the five
pathologically described polyps were adenomas; the last
polyp was identified as a sessile serrated polyp.
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The most recent colonoscopy, performed in December
2018, showed 20 polyps, in which all pathologically
described polyps were tubular adenomas with low dys-
plasia. The patient has developed 133 polyps so far and
has declined undergoing a recommended colectomy. He
was referred to genetic counseling, and an analysis of a
colorectal cancer gene panel consisting of 17 genes was
performed (APC, BMPR1A, CDH1, EPCAM, GREM1,
MLH1, MSH2, MSH6, MUTYH, NTHL1, PMS2, POLD1,
POLE, PTEN, SMAD4, STK11, TP53). A previously
reported homozygous nonsense variant (NM_002528):
c.268C>T, p. Gln90Ter in the NTHL1 gene was identified.
No alterations were found in the other examined genes.
As other cancer types have been described in patients
with homozygous nonsense variants in NTHL1, a gas-
troscopy and a dermatological examination were per-
formed, finding no suspicious results. A urine cytology
test showed no malignant cells.
Patient 2
The 55-year-old sister of patient 1 presented with a
thyroid adenoma at age 40, which was later characterized
as a cold nodule.
Due to multiple colorectal polyps in her brother, the
patient underwent a colonoscopy, and a tubular adenoma
with moderate dysplasia was removed from the caecum at
age 45. She was referred to genetic counseling, and
genetic testing identified the same homozygous nonsense
variant, c.268C>T, in NTHL1.
A gastroscopy and a dermatological examination
revealed no suspicious findings.
A recent colonoscopy showed eight colorectal polyps,
which were removed. Four polyps were pathologically
reviewed, classifying three as tubular adenomas with low
dysplasia and one sessile serrated polyp. Mammography
and gynecological examination were conducted, revealing
no signs of breast or endometrial cancer, respectively.
Other family members
Person 3, the mother of patients 1 and 2, is an obligate
heterozygous carrier of the nonsense variant, c.268 C>T,
in NTHL1. At age 58, she was diagnosed with pulmonary
squamous cell carcinoma, having a smoking history of
67.5 pack-years. She had also undergone thyroidectomy
due to goiter, approximately at age 50. The patient died of
lung cancer at 66 years old.
Person 4, the father of patients 1 and 2, is also an
obligate heterozygous carrier of the NTHL1 variant and
has no neoplasms or thyroid-associated diseases.
The offspring of patients 1 and 2 are obligate hetero-
zygous carriers and are all healthy.
This study reports the first family with a homozygous
nonsense variant in the NTHL1 gene in Denmark.
Globally, 18 families (30 individuals) with biallelic
NTHL1 variants have been reported4. The majority
(N= 23) of the reported patients are homozygous for
the same nonsense variant: c.268C>T. Five of the
reported patients are compound heterozygous indivi-
duals. Four of them have the c.268C>T, NTHL1 variant
(Table 1 in ref. 5). c.268C>T is the most frequent loss-
of-function variant in NTHL1, with an allele count of
400 (allele frequency of 0.14%) according to gnomAD
browser
(N= 141,111 exomes), all in a heterozygous state, with
the highest frequency in the European Finnish popula-
tion (0.35%) (http://gnomad.broadinstitute.org/variant/
16-2096239-G-A).
This family further expands the phenotypic spectrum
linked to NTHL1-associated polyposis and raises the total
number of families to 19 (32 individuals).
Previously, one individual with biallelic variants in
NTHL1 has been reported with thyroid cancer, diagnosed
at age 605. Patient 2 in this study, a homozygous carrier of
Fig. 1 The pedigree shows the first identified Danish family carrying a
homozygous nonsense variant in NTHL1
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the pathogenic NTHL1 variant, developed thyroid ade-
noma at age 40. Her mother (person 3) had undergone a
thyroidectomy due to a thyroid abnormality. No specifi-
cation of the thyroid abnormality can be made as no
medical records or tissue from the thyroidectomy of
person 3 can be found.
Papillary thyroid cancer, thyroid nodules, and multi-
nodular goiter have been reported in patients with FAP
and MAP6,7, suggesting a link between thyroid abnorm-
alities and NAP, although disorders of the thyroid gland
can be associated with several other genetic diseases,
which has not been analyzed in this family.
Moreover, studies have shown that heterozygous car-
riers of pathogenic MUTYH variants have twice the
population risk of developing colorectal adenomas and
endometrial cancer and three times the population risk of
developing liver and gastric cancer8. One study suggested
no increased risk of developing colorectal adenomas in
individuals heterozygous for the pathogenic NTHL1 var-
iant9. None of the heterozygous carriers in the current
family had a colonoscopy performed.
However, reported manifestations found in obligate
NTHL1 heterozygous carriers in the literature may sug-
gest a heightened risk of developing other neoplasms.
Significantly, one female was diagnosed with an endo-
metrial tumor at age 41, and one male was diagnosed with
gastric cancer at age 53. One heterozygous female carrier
of the c.268C>T variant was diagnosed with two unde-
scribed tumors. The number of NTHL1 families is very
limited, and only a few NTHL1 heterozygous patients are
reported with symptoms, so no definite conclusion can
be drawn.
Patient 1 developed 133 colorectal polyps by the age of
58, 55 of which developed during a 6-month period. This
observation is important when considering the natural
history of colorectal polyposis associated with NTHL1
mutations and corroborates the current recommendation
of colectomy when a considerable number of adenomas
are identified. This case report is the second to describe a
patient with a pathogenic homozygous NTHL1 variant
affected with >100 colorectal polyps, both being males10.
Previously, only four reported biallelic NTHL1 variant
carriers have been described without malignant neo-
plasms, raising the number to six out of 32 patients
without any malignant neoplasms when including the
siblings. This observation is certainly age-dependent, and
both reported patients have also been under clinical sur-
veillance with short intervals, which may contribute to
finding no malignant neoplasms.
In conclusion, none of the reported siblings, aged 55
and 58 years, developed malignant neoplasms; however,
the median age at diagnosis for colorectal cancer in
NTHL1 homozygous or compound heterozygous carriers
is 59 years for men and 64 years for women5.
Moreover, we have observed thyroid abnormalities in
both heterozygote and homozygote carriers in this family.
Studies of larger cohorts of individuals with NTHL1 var-
iants in both heterozygous and homozygous states can
further delineate the phenotypic spectrum.
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